213) th before and during adoption of COVID-19 control measures. |
214) n to mitigate the effects of COVID-19 and control measures. |
215) terventions, alongside enhanced infection control measures. |
216) tion is crucial to inform the appropriate control measures. |
217) e case for studies investigating societal control measures. |
218) alysis of spinal cords from TG2-A-cKO and control mice 3 days post-injury identified |
219) erely compromised immune-deficient (SCID) control mice compared with the PXB chimeri |
220) We used three sets of knock-in and control mice in which one Taar1 allele was |
221) real-world PM2.5 for 3 months, while the control mice inhaled filtered air. |
222) to-plasma Kpuu from PXB chimeric and SCID control mice were also compared, and rosuv |
223) ge in the phosphate buffer saline-treated control mice. |
224) erin-CreERT2/Igf1rf/f mice as compared to control mice. |
225) cted to colitis versus untreated, healthy control mice. |
226) gami platforms, which allow for nanoscale control over ligand distances without inte |
227) such a pathway, through which it can gain control over the maintenance of intracellu |
228) nline methods, the researcher has limited control over the participants' listening e |
229) consent to empower neurotechnology users' control over their data, (3) new methods o |
230) re is critical to enable them to increase control over their disease by better under |
231) n with the patient exerting an element of control over their target-site propofol co |
232) In conclusion, perceived limited control over what is eaten due to various |
233) 793 single-nucleus transcriptomes from 17 control subjects and AD-affected individua |
234) CH patients and control subjects were comparable regarding |
235) gle-cell RNA-sequencing data from healthy control subjects were used as references t |
236) y replacing TnC in myofibers from healthy control subjects with recombinant, mutant |
237) erved differences in DSC curves of LC and control subjects. |
238) tween AD-affected individuals and healthy control subjects. |
239) FV antibody staining, and (4) competitive control with IsoLG prior to the staining. |
240) In spite of effective seizure control with PLP, approximately 56% of pat |
241) ere designed to measure cognitive impulse control with a stop signal task (SST; N |
242) protein-energy requirements, and glycemic control with nutrition (acute COVID-19); a |
243) is one of the latest advancements in HIV control with the potential to overcome ora |
244) ill combine pandemic spread modelling and control, with economic models. |
245) mpared binary reinforcement training to a control condition of massed practice witho |
|